Senbing Zhang, Yanzhu Pu, Jianning Liu, Lewen Li, Chibing An, Yumin Wu, Wenjie Zhang, Wenxia Zhang, Song Qu, Wenjun Yan
( R , S )- and ( S )-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that ( R )-ketamine has a more efficient and lasting antidepressant effect with fewer side effects compared to ( R , S )- and ( S )-ketamine. However, a recent small-sample randomized controlled trial found that although ( R )-ketamine has a lower incidence of adverse reactions in adult TRD treatment, its antidepressant efficacy is not superior to the placebo group, indicating its antidepressant advantage still needs further verification and clarification...
2024: Frontiers in Pharmacology